TRXB

10.3156.12%
TA

Travis Alan Coy

Independent Director

Mr. Travis Alan Coy, M.B.A., serves as Chief Financial Officer, Executive Vice President & Head of Corporate Development at Immunocore Holdings plc from January 1, 2025. Mr. Coy has been a Director at Prevail Therapeutics Inc. since January 21, 2021. Mr. Coy serves as an Independent Director of TRex Bio, Inc from November 2021. Mr. Coy leads business development transaction and M&A execution across Eli Lilly’s therapeutic areas. His leadership, responsibilities and experience range from managing and developing the strategic and economic analyses of transactions (M&A, licensing and equity) to leading negotiations to having had financial leadership of alliances. He had been an Independent Non-Executive Director at Immunocore Holdings plc (formerly known as Immunocore Holdings Limited) since September 2019 until January 1, 2025. Mr. Coy is Vice President, Head of Transactions and M&A, Corporate Business Development for Oncology and Diagnostics at Eli Lilly and Company, a position he has held since October 2019. Prior to this role, Mr. Coy had a variety of finance and business development experiences at Lilly, where he has worked since 2003, including positions as Vice President, Transactions - Oncology and Diagnostics; Vice President of Transactions - Cardiometabolic Diseases, Drug Delivery and Devices; Head of Business Development for Cardiometabolic Diseases, Drug Delivery, Device and Connected Solution, Finance Director of the Oncology Business Unit; Director of Investor Relations; Director of Corporate Finance and Investment Banking; and other financial controllership roles. Before transitioning to finance and business development, he was a chemist in Lilly’s research laboratories and a production manager for Milliken & Company. Mr. Coy earned his MBA from the Ross School of Business at the University of Michigan and his BS in Chemistry from Rose-Hulman Institute of Technology.

Positions